Condition (MeSH)
Polycystic Kidney, Autosomal Recessive
ClinicalTrials.gov lists 8 trials for Polycystic Kidney, Autosomal Recessive or a narrower condition beneath it. Otsuka Pharmaceutical Development & Commercialization, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
8 of the 8 trials are tagged with Polycystic Kidney, Autosomal Recessive itself; the rest are tagged with a narrower condition beneath it.
When did Polycystic Kidney, Autosomal Recessive trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2024 | 2 |
| 2023 | 1 |
| 2022 | 1 |
| 2017 | 1 |
| 2011 | 1 |
| 2009 | 1 |
| 2003 | 1 |
No forecast is made for this condition: it averages 0.8 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Polycystic Kidney, Autosomal Recessive trials in? (3)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 2 |
| Observational | 5 |
How many Polycystic Kidney, Autosomal Recessive trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 5 |
| Completed | 2 |
| Withdrawn | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Polycystic Kidney, Autosomal Recessive trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 |
| Kadmon Corporation, LLC | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
Which publications cover Polycystic Kidney, Autosomal Recessive? (10)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Progress, challenges, and pragmatic concessions in predicting relative risk of kidney survival in ARPKD. | Kidney international | 2025 | Yes |
| Epidemiology and outcomes of pediatric autosomal recessive polycystic kidney disease in the Middle East and North Africa. | Pediatric nephrology (Berlin, Germany) | 2024 | Yes |
| Multi-parametric MRI of kidney disease progression for autosomal recessive polycystic kidney disease: mouse model and initial patient results. | Pediatric research | 2021 | Yes |
| Rapid B<sub>1</sub>-Insensitive MR Fingerprinting for Quantitative Kidney Imaging. | Radiology | 2021 | Yes |
| Neonatal renal cystic diseases. | The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians | 2018 | Yes |
Showing 5 of 10 publications.
Prevalence (4)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Autosomal recessive polycystic kidney disease | Point prevalence | Unknown | Europe | Not stated | Exact |
| Autosomal recessive polycystic kidney disease | Prevalence at birth | 1-9 / 100 000 | Germany | Not stated | Exact |
| Autosomal recessive polycystic kidney disease | Point prevalence | Unknown | Europe | Not stated | Exact |
| Autosomal recessive polycystic kidney disease | Prevalence at birth | 1-9 / 100 000 | Germany | Not stated | Exact |
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Autosomal recessive polycystic kidney disease | 731 | Exact | Orphanet Rare Disease Ontology (ORDO) |
| Autosomal recessive polycystic kidney disease | 731 | Exact | Orphadata Science knowledge files, Product 1 |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials and sub-conditions in mesh.
Not computed for conditions with fewer than 10 trials: drugs tested.